One way in which tumor cells mediate a checkpoint, or “brake” on T cell activation and thus anti-tumor immunity, is by expressing CTLA-4, a B7 ligand and an inhibitory homolog of CD28 (55) (Figure 1). This evidence concerns the gene CTLA4 and neoplasm.